Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
OTCMKTS:LYRA

Lyra Therapeutics Earnings Date & Estimates

Lyra Therapeutics logo
$0.19 0.00 (0.00%)
As of 11/2/2026 09:48 AM Eastern

Lyra Therapeutics is estimated to report earnings on Tuesday, November 17, 2026.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Lyra Therapeutics

Lyra Therapeutics is expected to post earnings of -$1.63 per share on revenue of $100 thousand. In the same quarter a year earlier Lyra Therapeutics reported -$3.38 per share on revenue of $25 thousand. Lyra Therapeutics last reported on November 12, 2025, posting -$3.38 per share and beating the -$5.98 consensus estimate. Lyra Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.63
Expected Revenue
$100 thousand
Prior-Year EPS
-$3.38
Prior-Year Revenue
$25 thousand
Expected Revenue Growth
+300.0%

Recent Track Record

Last Reported
Q3 2025
Last Quarter EPS
-$3.38 (Beat by +$2.60)
Last Quarter Revenue
$25 thousand
EPS Beat Rate
6 of last 8 quarters

Prepare for the Earnings Call

Lyra Therapeutics Earnings FAQ

Lyra Therapeutics (OTCMKTS:LYRA) is estimated to report earnings on Tuesday, November 17, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Lyra Therapeutics to post earnings of -$1.63 per share for the quarter.

The consensus revenue estimate for Lyra Therapeutics is $100 thousand for the quarter.

Lyra Therapeutics Earnings Headlines

Lyra Therapeutics Inc.
August 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/lyra/financials/cash-flow
Lyra Therapeutics Ends Major Office Sublease Agreement
April 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lyra-therapeutics-ends-major-office-sublease-agreement?utm_source=marketbeat.com&utm_medium=referral
Why Gerardo Del Real says wait before buying uranium stocks
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.tc pixel
November 3 at 1:00 AM  |  Digest Publishing (Ad)
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
April 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/17/3276116/0/en/lyra-therapeutics-inc-announces-intention-to-voluntarily-file-form-25-for-delisting-from-nasdaq-and-subsequent-deregistration-with-the-sec.html
After layoffs, Lyra Therapeutics exits Watertown and Waltham leases
April 14, 2026  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2026/04/13/lyra-terminates-leases.html
Treating allergic fungal rhinosinusitis in children
April 8, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/treating-allergic-fungal-rhinosinusitis-in-children/ar-AA20r233
See More Lyra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyra Therapeutics and other key companies, straight to your email.

About Lyra Therapeutics

Lyra Therapeutics (OTCMKTS:LYRA) is a biotechnology company focused on developing long-acting, locally administered treatments for diseases of the ear, nose and throat. The company’s programs are designed to deliver medication directly to the nasal passages, with the goal of improving treatment duration, reducing reliance on daily therapies and addressing limitations associated with conventional nasal sprays.

Lyra’s technology is based on its proprietary, bioresorbable nasal delivery platform, which is intended to provide controlled drug release over an extended period. Its primary programs included LYR-210, an investigational device designed to deliver mometasone furoate for the treatment of chronic rhinosinusitis, and LYR-220, a later-generation product candidate developed for patients with chronic rhinosinusitis, including those with nasal polyps.

Founded in 2005 and headquartered in Waltham, Massachusetts, Lyra has conducted its development activities primarily in the United States. Its lead products remain investigational and have not been established as approved treatments. The company has also evaluated strategic alternatives and reduced its operations following setbacks in clinical development.

View Lyra Therapeutics Profile
Earnings Tools